Thin melanoma: Still "excellent prognosis" disease?

Journal of Clinical Oncology

Volumn 22, Issue 18, 2004, Pages 3651-3653

  Halpern, A C ^a   Marghoob, A A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; EDITORIAL; HISTOPATHOLOGY; HUMAN; MELANOMA; METASTASIS; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; NOTE; PATHOLOGY; SKIN TUMOR; SURVIVAL;

HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL;

EID: 4644252338     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.921     Document Type: Editorial

References (28)

1. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
2. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
3. Freedberg IM, Eisen AZ, Wolff K, et al: Fitzpatrick's Dermatology in General Medicine (ed 6). New York, NY, McGraw-Hill, 2003
4. American Cancer Society, Cancer Facts and Figures 2004. New York, NY. American Cancer Society, 2004
5. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs, Nov 2002 Sub (1973-2000), (ed April 2003, based on the November 2002 submission.). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2003
6. Balch CM, Buzaid AC, Soong SJ, et al: New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Semin Surg Oncol 21:43-52, 2003
7. Sobin L, Wittekind C: TNM Classification of Malignant Tumors, 6th Edition. New York, Wiley, 2002
8. Greene F, Page D, Fleming I, et al: AJCC Cancer Staging Manual 6th Edition. New York, Springer Verlag, 2002
9. Ruiter DJ, Testori A, Eggermont AM, et al: The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group. Ann Oncol 12:9-11, 2001
10. Garbe C, Ellwanger U, Tronnier M, et al: The New American Joint Committee on Cancer staging system for cutaneous melanoma: A critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer 94:2305-2307, 2002
11. McKinnon JG, Yu XQ, McCarthy WH, et al: Prognosis for patients with thin cutaneous melanoma: Long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 98:1223-1231, 2003
12. Kalady MF, White RR, Johnson JL, et al: Thin melanomas: Predictive lethal characteristics from a 30-year clinical experience. Ann Surg 238:528-535, 2003
13. Owen SA, Sanders LL, Edwards LJ, et al: Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. Cancer 91:983-991, 2001
14. Gimotty PA, Guerry D, Ming ME, et al: Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer Staging. J Clin Oncol 22:3668-3676, 2004
15. Lefevre M, Vergier B, Balme B, et al: Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol 27:717-724, 2003
16. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al: Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 36:347-350, 2003
17. Bedrosian I, Paries MB, Guerry Dt, et al: Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 7:262-267, 2000
18. Clark WH Jr, Elder DE, Guerry D 4th, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
19. Tuthill RJ, Unger JM, Liu PY, et al: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118:504-511, 2002
20. Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996
21. Schuchter L, Schultz DJ, Synnestvedt M, et al: A prognostic model for predicting 10-year survival in patients with primary melanoma: The Pigmented Lesion Group. Ann Intern Med 125:369-375, 1996
22. Leiter U, Buettner PG, Eigentler TK, et al: Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. J Clin Oncol 22:3660-3667, 2004
23. Dessureault S, Soong SJ, Ross MI, et al: Improved staging of node-negative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8:766-770, 2001
24. Queirolo P, Taveggia P, Gipponi M, et al: Sentinel lymph node biopsy in melanoma patients: The medical oncologist's perspective. J Surg Oncol 85:162-165, 2004
25. Jacobs IA, Chang CK, DasGupta TK, et al: Role of sentinel lymph node biopsy in patients with thin (< 1 mm) primary melanoma. Ann Surg Oncol 10:558-561, 2003
26. Corsetti RL, Allen HM, Wanebo HJ: Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 7:456-160, 2000
27. Agnese DM, Abdessalam SF, Burak WE Jr, et al: Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 134:542-558, 2003
28. Compton CC, Barnhill R, Wick MR, et al: Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 127:1253-1262, 2003